241 related articles for article (PubMed ID: 9164968)
1. A novel mechanism of alternative pathway complement activation accounts for the deposition of C3 fragments on CR2-expressing homologous cells.
Schwendinger MG; Spruth M; Schoch J; Dierich MP; Prodinger WM
J Immunol; 1997 Jun; 158(11):5455-63. PubMed ID: 9164968
[TBL] [Abstract][Full Text] [Related]
2. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
Mold C; Nemerow GR; Bradt BM; Cooper NR
J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
[TBL] [Abstract][Full Text] [Related]
3. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
Marquart HV; Svehag SE; Leslie RG
J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
[TBL] [Abstract][Full Text] [Related]
4. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line.
Hatzfeld A; Fischer E; Levesque JP; Perrin R; Hatzfeld J; Kazatchkine MD
J Immunol; 1988 Jan; 140(1):170-5. PubMed ID: 2826586
[TBL] [Abstract][Full Text] [Related]
5. Mutation of residues in the C3dg region of human complement component C3 corresponding to a proposed binding site for complement receptor type 2 (CR2, CD21) does not abolish binding of iC3b or C3dg to CR2.
Diefenbach RJ; Isenman DE
J Immunol; 1995 Mar; 154(5):2303-20. PubMed ID: 7868901
[TBL] [Abstract][Full Text] [Related]
6. The requirement of localized, CR2-mediated, alternative pathway activation of complement for covalent deposition of C3 fragments on normal B cells.
Olesen EH; Johnson AA; Damgaard G; Leslie RG
Immunology; 1998 Feb; 93(2):177-83. PubMed ID: 9616366
[TBL] [Abstract][Full Text] [Related]
7. Evidence for an important interaction between a complement-derived CD21 ligand on follicular dendritic cells and CD21 on B cells in the initiation of IgG responses.
Qin D; Wu J; Carroll MC; Burton GF; Szakal AK; Tew JG
J Immunol; 1998 Nov; 161(9):4549-54. PubMed ID: 9794381
[TBL] [Abstract][Full Text] [Related]
8. [Role of the complement C3 protein in the control of the specific immune response].
Villiers CL; Villiers MB; Marche PN
Ann Biol Clin (Paris); 1999; 57(2):127-35. PubMed ID: 10210739
[TBL] [Abstract][Full Text] [Related]
9. B lymphocytes and macrophages release cell membrane deposited C3-fragments on exosomes with T cell response-enhancing capacity.
Papp K; Végh P; Prechl J; Kerekes K; Kovács J; Csikós G; Bajtay Z; Erdei A
Mol Immunol; 2008 Apr; 45(8):2343-51. PubMed ID: 18192019
[TBL] [Abstract][Full Text] [Related]
10. Expression, molecular association, and functions of C3 complement receptors CR1 (CD35) and CR2 (CD21) on the human T cell line HPB-ALL.
Delibrias CC; Fischer E; Bismuth G; Kazatchkine MD
J Immunol; 1992 Aug; 149(3):768-74. PubMed ID: 1386093
[TBL] [Abstract][Full Text] [Related]
11. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21).
Esparza I; Becherer JD; Alsenz J; De la Hera A; Lao Z; Tsoukas CD; Lambris JD
Eur J Immunol; 1991 Nov; 21(11):2829-38. PubMed ID: 1834472
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
13. CR2 ligands modulate human B cell activation.
Bohnsack JF; Cooper NR
J Immunol; 1988 Oct; 141(8):2569-76. PubMed ID: 2459218
[TBL] [Abstract][Full Text] [Related]
14. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3D/EBV receptor.
Pernegger G; Schulz TF; Hosp M; Myones BL; Petzer AL; Eigentler A; Böck G; Wick G; Dierich MP
Immunology; 1988 Oct; 65(2):237-41. PubMed ID: 2461345
[TBL] [Abstract][Full Text] [Related]
15. CR2-mediated activation of the complement alternative pathway results in formation of membrane attack complexes on human B lymphocytes.
Nielsen CH; Marquart HV; Prodinger WM; Leslie RG
Immunology; 2001 Dec; 104(4):418-22. PubMed ID: 11899427
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
17. Complement receptors type 1 (CR1, CD35) and 2 (CR2, CD21) cooperate in the binding of hydrolyzed complement factor 3 (C3i) to human B lymphocytes.
Leslie RG; Prodinger WM; Nielsen CH
Eur J Immunol; 2003 Dec; 33(12):3311-21. PubMed ID: 14635039
[TBL] [Abstract][Full Text] [Related]
18. The structural basis for complement receptor type 2 (CR2, CD21)-mediated alternative pathway activation of complement: studies with CR2 deletion mutants and vaccinia virus complement-control protein-CR2 chimeras.
Johnson AA; Mirowski Rosengard A; Skjodt K; Ahearn JM; Leslie RG
Eur J Immunol; 1999 Dec; 29(12):3837-44. PubMed ID: 10601991
[TBL] [Abstract][Full Text] [Related]
19. Two modes of homologous C3 deposition on Ramos Burkitt's lymphoma cell substrains co-expressing DAF (CD55), CD59, and CR2 (CD21), and on cells lacking them.
Seya T; Hara T; Okada M; Kojima A; Matsumoto M; Akedo H
Int Immunol; 1992 Dec; 4(12):1361-71. PubMed ID: 1283697
[TBL] [Abstract][Full Text] [Related]
20. Herpes simplex virus glycoprotein C: molecular mimicry of complement regulatory proteins by a viral protein.
Huemer HP; Wang Y; Garred P; Koistinen V; Oppermann S
Immunology; 1993 Aug; 79(4):639-47. PubMed ID: 8406590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]